Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nichols

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Parasites & Vectors|January 7, 2021
Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable useVicky Wilkinson, Kotaro Takano, David Nichols, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 6, 2024
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftorJennifer T Duong, Christopher E Pope, Hillary S Hayden, et al.
Pulmonary Circulation|January 7, 2020
Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertensionVineet Agrawal, Niki Fortune, Sheeline Yu, et al.
Parasites & Vectors|March 6, 2021
Correction to: Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable useVicky Wilkinson, Kotaro Takano, David Nichols, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|March 23, 2012
A programmable laboratory testbed in support of evaluation of functional brain activation and connectivityRandall L Barbour, Harry L Graber, Yong Xu, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 7, 2025
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise studyJennifer T Duong, Hillary S Hayden, Adrian J Verster, et al.
Frontiers in Cell and Developmental Biology|May 11, 2026
Correction: <i>Lmx1a</i> is essential for marginal cell differentiation and stria vascularis formationJustine M Renauld, Igor Y Iskusnykh, Ebenezer N Yamoah, et al.
Frontiers in Cell and Developmental Biology|March 20, 2025
<i>Lmx1a</i> is essential for marginal cell differentiation and stria vascularis formationJustine M Renauld, Igor Y Iskusnykh, Ebenezer N Yamoah, et al.
Annals of the American Thoracic Society|July 23, 2024
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic FibrosisNicole Mayer-Hamblett, Alex H Gifford, Margaret Kloster, et al.
Science Translational Medicine|January 8, 2025
Hypoxia-inducible factor 2 regulates alveolar regeneration after repetitive injury in three-dimensional cellular and in vivo modelsA Scott McCall, Sergey Gutor, Hari Tanjore, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Parasites & Vectors|January 7, 2021
Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable useVicky Wilkinson, Kotaro Takano, David Nichols, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 6, 2024
Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftorJennifer T Duong, Christopher E Pope, Hillary S Hayden, et al.
Pulmonary Circulation|January 7, 2020
Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertensionVineet Agrawal, Niki Fortune, Sheeline Yu, et al.
Parasites & Vectors|March 6, 2021
Correction to: Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable useVicky Wilkinson, Kotaro Takano, David Nichols, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|March 23, 2012
A programmable laboratory testbed in support of evaluation of functional brain activation and connectivityRandall L Barbour, Harry L Graber, Yong Xu, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 7, 2025
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise studyJennifer T Duong, Hillary S Hayden, Adrian J Verster, et al.
Frontiers in Cell and Developmental Biology|May 11, 2026
Correction: <i>Lmx1a</i> is essential for marginal cell differentiation and stria vascularis formationJustine M Renauld, Igor Y Iskusnykh, Ebenezer N Yamoah, et al.
Frontiers in Cell and Developmental Biology|March 20, 2025
<i>Lmx1a</i> is essential for marginal cell differentiation and stria vascularis formationJustine M Renauld, Igor Y Iskusnykh, Ebenezer N Yamoah, et al.
Annals of the American Thoracic Society|July 23, 2024
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic FibrosisNicole Mayer-Hamblett, Alex H Gifford, Margaret Kloster, et al.
Science Translational Medicine|January 8, 2025
Hypoxia-inducible factor 2 regulates alveolar regeneration after repetitive injury in three-dimensional cellular and in vivo modelsA Scott McCall, Sergey Gutor, Hari Tanjore, et al.
Pageof 8